Form4insider filings, from the source

SEC Form 4 · accession 0001567619-18-007050

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Nov 26, 2018
Accepted (ET)
Nov 28, 2018 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockNov 26, 2018M5,500$3.648A19,200D
Common StockF2,F3Nov 26, 2018S1,556$151.71D17,644D
Common StockF2,F4Nov 26, 2018S1,644$152.49D16,000D
Common StockF2,F5Nov 26, 2018S1,500$154.00D14,500D
Common StockF2,F6Nov 26, 2018S600$155.30D13,900D
Common StockNov 26, 2018S200$156.45D13,700D
Common StockNov 27, 2018M2,443$3.648A16,143D
Common StockNov 27, 2018M2,057$13.67A18,200D
Common StockF2,F7Nov 27, 2018S949$138.08D17,251D
Common StockF2,F8Nov 27, 2018S1,170$138.83D16,081D
Common StockF2,F9Nov 27, 2018S300$140.13D15,781D
Common StockF2,F10Nov 27, 2018S500$141.69D15,281D
Common StockF2,F11Nov 27, 2018S500$143.08D14,781D
Common StockF2,F12Nov 27, 2018S200$143.92D14,581D
Common StockNov 27, 2018S100$144.97D14,481D
Common StockF2,F13Nov 27, 2018S300$147.06D14,181D
Common StockNov 27, 2018S81$147.99D14,100D
Common StockF2,F14Nov 27, 2018S200$149.46D13,900D
Common StockNov 27, 2018S200$151.55D13,700D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F15$3.648Nov 26, 2018M5,500D—Jun 18, 2024Common Stock5,50042,769D
Employee Stock Option (Right to Buy)F15$3.648Nov 27, 2018M2,443D—Jun 18, 2024Common Stock2,44340,326D
Employee Stock Option (Right to Buy)F16$13.67Nov 27, 2018M2,057D—Dec 18, 2024Common Stock2,05787,943D

Explanation of responses